Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-07-03

Clinical Trial Update: Varenicline and Smoking Cessation in Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating varenicline for smoking cessation in individuals with schizophrenia. Results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Varenicline (varenicline)

Snippet

Sponsor: University of Minnesota | Conditions: Schizophrenia, Smoking Cessation | Phase 2 | Status: COMPLETED | Results posted: 2014-07-03